Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities

Affiliations

¹ In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. Joost.Boeckmans@vub.be.
² Metabolic Liver Research Center, Department of Medicine, University Medical Center Mainz, Mainz, Germany. Joost.Boeckmans@vub.be.
³ In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
⁴ Metabolic Liver Research Center, Department of Medicine, University Medical Center Mainz, Mainz, Germany.

Editorial

Joost Boeckmans et al. Arch Toxicol. 2023 Jun.

. 2023 Jun;97(6):1825-1827.

doi: 10.1007/s00204-023-03498-0. Epub 2023 May 6.

¹ In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. Joost.Boeckmans@vub.be.
² Metabolic Liver Research Center, Department of Medicine, University Medical Center Mainz, Mainz, Germany. Joost.Boeckmans@vub.be.
³ In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
⁴ Metabolic Liver Research Center, Department of Medicine, University Medical Center Mainz, Mainz, Germany.

No abstract available

References

1. Amangurbanova M, Huang DQ, Loomba R (2023) Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 57:37–51. https://doi.org/10.1111/apt.17292 - DOI - PubMed
1. Boeckmans J, Natale A, Rombaut M et al (2020) Anti-NASH drug development hitches a lift on PPAR agonism. Cells 9:1–20. https://doi.org/10.3390/cells9010037 - DOI
1. Boeckmans J, Natale A, Rombaut M et al (2021) Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biol Toxicol 37:293–311. https://doi.org/10.1007/s10565-020-09544-2 - DOI - PubMed
1. Boeckmans J, Gatzios A, Schattenberg JM et al (2023) PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int. https://doi.org/10.1111/liv.15533 - DOI - PubMed
1. Cherubini A, Casirati E, Tomasi M, Valenti L (2021) PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 25:1033–1043. https://doi.org/10.1080/14728222.2021.2018418 - DOI - PubMed